Literature DB >> 6252164

Cefotaxime in the treatment of severe paediatric infections.

C J Papadatos, D A Kafetzis, J Kanarios.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252164     DOI: 10.1093/jac/6.suppl_a.243

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

Review 1.  Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval.

Authors:  G L Kearns; R A Young; R F Jacobs
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

2.  Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci.

Authors:  H Lode; P D Glatzel
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

4.  Clinical pharmacology of cefotaxime in pediatric patients.

Authors:  D A Kafetzis; D C Brater; J Kanarios; C A Sinaniotis; C J Papadatos
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

5.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

Review 6.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

7.  Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.

Authors:  M D Reed; C A O'Brien; S C Aronoff; J D Klinger; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.